2022
Implication of IL-7 receptor alpha chain expression by CD8+ T cells and its signature in defining biomarkers in aging
Shin M, Park H, Young J, Kang I. Implication of IL-7 receptor alpha chain expression by CD8+ T cells and its signature in defining biomarkers in aging. Immunity & Ageing 2022, 19: 66. PMID: 36544153, PMCID: PMC9768896, DOI: 10.1186/s12979-022-00324-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsT cellsImmune agingHost defenseIL-7 receptor alpha chainFrequencies of naïveT cell subsetsAlpha chain expressionAssociation of CD8Age-associated conditionsReceptor alpha chainMemory CD8Treatment of illnessCell subsetsInflammatory disordersIL-7RαCD8High riskImmune functionTherapeutic interventionsImmune systemPotential biomarkersGene signatureChain expressionOlder adultsBiomarkers
2020
Defining heterogeneity and biological signature in human effector memory CD8+ T cells expressing different levels of IL-7 receptor alpha by high-dimensional analysis
Shin M, Kim D, Park H, Dong X, Koumpouras F, Kang I. Defining heterogeneity and biological signature in human effector memory CD8+ T cells expressing different levels of IL-7 receptor alpha by high-dimensional analysis. The Journal Of Immunology 2020, 204: 154.19-154.19. DOI: 10.4049/jimmunol.204.supp.154.19.Peer-Reviewed Original ResearchHuman effector memory CD8EM CD8Effector memory CD8T cellsIL-7RαMemory CD8Cell subsetsIL-7 receptor alphaIL-7 receptor alpha chainT cell subsetsCo-stimulatory moleculesT cell heterogeneityHigh-dimensional single-cell analysisReceptor alpha chainLupus patientsImmune landscapeCell surface moleculesHeterogeneous cell subsetsT-betCD8Effector functionsDifferential expressionReceptor alphaSingle-cell RNA-seq analysisPathologic conditions
2016
Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment.
Kim J, Kang Y, Shin M, Deshpande H, Hurwitz M, Roberts J, Cardinale J, Narayana A, Kang I, Petrylak D. Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment. Journal Of Clinical Oncology 2016, 34: 295-295. DOI: 10.1200/jco.2016.34.2_suppl.295.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPeripheral blood mononuclear cellsT cell immunityT cellsCell immunityOsseous metastasesMetastatic castration-resistant prostateCastration-resistant prostate cancerIL-7 receptor alpha chainRadium-223 treatmentEffector memory CD8PD-1 expressionEffector T cellsDeath protein 1Resistant prostate cancerCastration-resistant prostateBlood mononuclear cellsFollowing time pointsCocktail of antibodiesHost immune systemReceptor alpha chainCalcium mimeticEligible patientsEM CD8Median PSA